Drug Trial Radar · NCT07221253
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
Dec 4, 2025
Primary completion
Jul 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
Conditions
- Biliary Tract Cancer
Interventions
RilvegostomigDrug
Rilvegostomig IV (intravenous) Q3W
DurvalumabDrug
Durvalumab 1500mg IV (intravenous) Q3W for up to 8 cycles (21days). Then Q4W.
Gemcitabine/CisplatinDrug
Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in the PDL1 ≥ 1% populationTime frame: approximately 4 years
Locations
183 sites in 19 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Tucson, Arizona · Recruiting
Research Site
Duarte, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Orange, California · Recruiting
Research Site
Palo Alto, California · Recruiting
Research Site
Aurora, Colorado · Recruiting
Research Site
Hartford, Connecticut · Recruiting
Research Site
New Haven, Connecticut · Recruiting
Research Site
Washington D.C., District of Columbia · Recruiting
Research Site
Washington D.C., District of Columbia · Not yet recruiting
Research Site
Gainesville, Florida · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Miami, Florida · Not yet recruiting
Research Site
Marietta, Georgia · Recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Indianapolis, Indiana · Not yet recruiting
Research Site
Louisville, Kentucky · Recruiting
Research Site
Louisville, Kentucky · Withdrawn
Research Site
Baltimore, Maryland · Recruiting
Research Site
Ann Arbor, Michigan · Not yet recruiting
Research Site
Detroit, Michigan · Not yet recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
Omaha, Nebraska · Not yet recruiting
Research Site
Santa Fe, New Mexico · Recruiting
Research Site
Mineola, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Withdrawn
Research Site
Oklahoma City, Oklahoma · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Lancaster, Pennsylvania · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Providence, Rhode Island · Recruiting
Research Site
Pierre, South Dakota · Recruiting
Research Site
Sioux Falls, South Dakota · Recruiting
Research Site
Nashville, Tennessee · Not yet recruiting
Showing 40 of 183 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.